0(0)

M.D. PhD Behnam Sadeghi – Decidua stromal cells (DSC), new and promising source of stromal cells for acute inflammatory disorders

  • Duration 22m 31s
  • Total Enrolled 0
  • Last Update February 18, 2020

Description

 

BASIC SCIENCE IN REGENERATIVE MEDICINE PANEL

GLOBAL REGENERATIVE CONGRESS 6-8 SEPTEMBER 2019

 

There is an urgent need for effective therapy for severe acute GVHD. Results of GVHD therapies beyond 6 months are rarely reported. We here report a median follow-up of 4 years. We introduced mesenchymal stromal cells as therapy for severe acute GVHD, with a dramatic response in some, but not all patients. The placenta protects the haploidentical fetus from the mother’s immune system during pregnancy. We found that maternal stromal cells from the fetal membrane, so called decidua stromal cells (DSCs) were more immunosuppressive than other sources of stromal cells.

We treated 21 patients, median 49 years of age (range 1.6-72) for severe acute GVHD. All had biopsy proven gastro-intestinal GVHD. All were steroid refractory,11 after >7days or with progression and 10 after >3 days. DSCs were given at a median dose of 1.2 (0.9-2.9) x 106 cells/kg and 2(1-6) doses, given one week apart. Viability of frozen and thawed DSCs was 95% (89-100) and cell passage was 4 (2-4).

Complete resolution of GVHD was seen in 11 patients and 10 had a partial response. The cumulative incidence of chronic GVHD was 52%. Six had mild, 4 moderate and one severe, based on the NIH overall GVHD severity scoring. Nine patients died, 3 from relapse, 1 acute GVHD and septicemia, 1 zygomycetes infection, 1 liver insufficiency, 1 cerebral hemorrhage, 1multiorgan failure and 1 chronic GVHD with obstructive bronchiolitis. Four years transplant related mortality was 28.6% and overall survival was 57%. Survival was not significantly worse (p=0.33) than 66% for all 293 patients undergoing allogeneic hematopoietic cell transplantation during the same period 2012-2015.

To conclude, DSCs seems to be a promising new cell based therapy for severe acute GVHD and other acute inflammatory disorders. Randomized trials are under way.

How to watch the full length videos?

If you want to watch the whole videos click the buy button and follow the instructions – you will be asked to register as a member or as a free registration.

Becoming a Member of the Academy grants you exclusive access to the community of Regenerative Medicine. You will receive 10% discount from the regular price of all videos. The membership also grants you access to the Membership panel where you can contact the Academy’s Key Opinion Leaders, read validated articles in Regenerative Medicine and contact with colleagues from all over the world.

How to watch only selected videos?

Go to the Videos category.
Click on the panel you have selected.
Add to your cart the separate videos you want to watch.
Complete the buying process either with a membership account (10% fee reduction on all videos) or a free account.
Watch the videos, ask questions in the QnA section, connect with colleagues and enjoy.

Upon completion of the whole course you will be issued a Certificate of Acknowledgement for completing the online education form of the Global Regenerative Academy.

Topics for this course

1 Lessons22m 31s

M.D. PhD Behnam Sadeghi – Decidua stromal cells (DSC), new and promising source of stromal cells for acute inflammatory disorders

M.D. PhD Behnam Sadeghi – Decidua stromal cells (DSC), new and promising source of stromal cells for acute inflammatory disorders00:22:31
$35.00 excl. transaction fee
Choose language »